Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/30119
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Naba, NM | - |
dc.contributor.author | Tolay, N | - |
dc.contributor.author | Erman, B | - |
dc.contributor.author | Sayi Yazgan, A | - |
dc.date.accessioned | 2024-11-14T09:18:55Z | - |
dc.date.available | 2024-11-14T09:18:55Z | - |
dc.date.issued | 2020-01 | - |
dc.identifier | ORCiD: Ayça Sayi Yazgan https://orcid.org/0000-0002-9015-8244 | - |
dc.identifier.citation | Naba, N.M. et al. (2020) 'Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells', Turkish Journal of Biology, 44 (1), pp. 15 - 23. doi: 10.3906/biy-1909-12. | en_US |
dc.identifier.issn | 1300-0152 | - |
dc.identifier.uri | https://bura.brunel.ac.uk/handle/2438/30119 | - |
dc.description.abstract | One of the most challenging problems in colorectal cancer (CRC) is resistance to chemotherapy drugs such as doxorubicin (DOX). The programmed death ligand-1 (PD-L1) is related to chemoresistance and is overexpressed in several human cancer cell types. Here, we investigated the changes in the expression of PD-L1 in DOX-treated CRC and breast cancer (BRC) cells. Also, to address PD-L1 regulation, we assessed expression levels of miR-140 and miR-34a, two microRNAs that can target the 3’ UTR region of the gene encoding PD-L1. HCT116 CRC and MDA-MB-231 BRC cells were treated with various doses of DOX in culture and PD-L1 expression was quantified using qRT-PCR, flow cytometry, and western blot analysis. We also evaluated PD-L1 localization in HCT116 cells by immunofluorescence. Next, we assessed expression of miR-140 and miR-34a in DOX-treated HCT116 and MDA-MB-231 cells. Finally, we investigated whether miR-140 targets the 3’ UTR of the gene encoding PD-L1 in HCT116 cells using the p2FP-RNAi RNAi reporter vector system. PD-L1 expression in HCT116 cells, while low at baseline, can be induced by treatment with 0.5 µM DOX. MDA-MB-231 baseline PD-L1 expression exceeded HCT116 cell maximal expression and decreased following DOX treatment. We further demonstrated that PD-L1 localizes to the cell surface in DOX-treated HCT116 cells. While miR-140 expression decreased in DOX-treated HCT116 cells, it increased in DOX-treated MDA-MB-231 cells. MiR-34a expression increased in both DOX-treated cell types. Finally, we present evidence for the regulation of PD-L1 by miR-140 in HCT116 cells. PD-L1 expression can increase following treatment with DOX in HCT116 cells but decrease in MDA-MB-231 cells, suggesting a distinct response to DOX in these two different cancer types. Also, a negative correlation between PD-L1 and miR-140 was observed in DOX-treated HCT116 cells, but not in MDA-MB-231 cells. | en_US |
dc.description.sponsorship | This study was supported by İstanbul Technical University, Department of Scientific Research Projects (ITÜ-BAP) (Project # 39555). | - |
dc.format.extent | 15 - 23 | - |
dc.format.medium | Print-Electronic | - |
dc.language.iso | en | en_US |
dc.publisher | TUBITAK Academic Journals | en_US |
dc.rights | Attribution 4.0 International | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.subject | PD-L1 | en_US |
dc.subject | doxorubicin | en_US |
dc.subject | miR-34a | en_US |
dc.subject | miR-140 | en_US |
dc.title | Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells | en_US |
dc.type | Article | en_US |
dc.identifier.doi | https://doi.org/10.3906/biy-1909-12 | - |
dc.relation.isPartOf | Turkish Journal of Biology | - |
pubs.issue | 1 | - |
pubs.publication-status | Published | - |
pubs.volume | 44 | - |
dc.identifier.eissn | 1303-6092 | - |
dc.rights.license | https://creativecommons.org/licenses/by/4.0/legalcode.en | - |
dc.rights.holder | The Author(s) | - |
Appears in Collections: | Dept of Life Sciences Research Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
FullText.pdf | Copyright © 2020 The Author(s). This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/). | 1.61 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License